Navigation Links
Promising new treatment option for women with recurrent ovarian cancer
Date:9/15/2008

Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

The combination, which importantly does not include a platinum drug, challenges the current standard of treatment for women whose cancer recurs at least 6 months after first-line treatment, said Associate Prof. Bradley J. Monk from the University of California Irvine Medical Center.

"This trial, which included almost two-thirds such women, challenges this traditional paradigm and suggests that a non-platinum doublet is also effective in this setting," he said. "Trabectedin represents a 'new chemical entity' in North America and if approved by the FDA, would be an important new option for women with recurrent ovarian cancer."

Trabectedin, a synthetic version of a compound first isolated from sea-squirts, has been granted marketing approval in Europe for the treatment of patients with advanced soft tissue sarcoma.

In the latest trial, an international group of researchers studied the combination in 672 women whose ovarian cancer had progressed after first-line therapy. Half the women received pegylated liposomal doxorubicin 30 mg/m2 over 60 min plus trabectedin 1.1mg/m2 over 3 hours every 3 weeks, the remainder received pegylated liposomal doxorubicin 50 mg/m2 alone every 4 weeks.

The median length of progression-free survival for women on the combination therapy was 7.3 months, the researchers found, compared to 5.8 months for those treated with the single drug. For those who had relapsed more than six months after the first-line therapy, the median progression-free survival time was 9.2 months for the combination treatment, compared to 7.5 months for patients in the other arm.

"This drug appears active in all sub-groups included in the trial, but like all agents is most active among those with longer time intervals since their front-line chemotherapy treatment," Prof. Monk said.

"Positive trials in recurrent ovarian cancer are rare and have almost always led to newly approved therapeutic regimens," he said. "This combination will undoubtedly be carefully evaluated by the FDA and if approved would give women with ovarian cancer another much-needed option."


'/>"/>

Contact: ESMO Press Office
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. UIC researchers find promising new targets for antibiotics
2. New book defines promising young field of adult neurogenesis
3. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
4. Cancer and arthritis therapy may be promising treatment for diabetes
5. Unique whey protein is promising supplement for strict PKU diet
6. Promising new drug targets identified for Huntingtons disease
7. Promising new nanotechnology for spinal cord injury
8. Biodesigns Rittmann offers promising perspectives on societys energy challenge
9. UIC researchers make promising finding in severe lung disease
10. New treatment approach promising for lymphoma patients in the developing world
11. Immunotherapy in high-risk pediatric sarcomas shows promising response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology: